دورية أكاديمية
[Evidence of GVHD/GVL in allogeneic hematopoietic stem cell transplantation from sex-mismatched donors].
| العنوان: | [Evidence of GVHD/GVL in allogeneic hematopoietic stem cell transplantation from sex-mismatched donors]. |
|---|---|
| المؤلفون: | Nakasone H; Division of Emerging Medicine for Integrated Therapeutics (EMIT), Center for Molecular Medicine, Jichi Medical University.; Division of Hematology, Jichi Medical University Saitama Medical Center. |
| المصدر: | [Rinsho ketsueki] The Japanese journal of clinical hematology [Rinsho Ketsueki] 2024; Vol. 65 (4), pp. 265-271. |
| نوع المنشور: | English Abstract; Journal Article |
| اللغة: | Japanese |
| بيانات الدورية: | Publisher: Japan Society Of Clinical Hematology Country of Publication: Japan NLM ID: 2984782R Publication Model: Print Cited Medium: Print ISSN: 0485-1439 (Print) Linking ISSN: 04851439 NLM ISO Abbreviation: Rinsho Ketsueki Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Tokyo : Japan Society Of Clinical Hematology Original Publication: Tokyo, Rinsho Ketsueki Kondankai. |
| مواضيع طبية MeSH: | Hematopoietic Stem Cell Transplantation*/adverse effects , Graft vs Host Disease*/immunology , Graft vs Host Disease*/etiology , Transplantation, Homologous* , Graft vs Leukemia Effect*/immunology , Tissue Donors*, Humans ; Female ; Male |
| مستخلص: | Hematopoietic cell transplantation (HCT) is considered a curative treatment for hematological malignancies. However, HCT recipients often face complications such as graft-versus-host disease (GVHD) and disease relapse. Clinical factors like age and HLA disparity are recognized as risks for GVHD. Notably, sex-mismatched HCT, particularly with female donors and male recipients (F→M), is reported to increase the risk of chronic GVHD. This adverse effect of F→M HCT is thought to result from allogeneic immune response against minor histocompatibility antigens encoded on the Y-chromosome of a male recipient (HY-antigens). Indeed, antibodies against HY-antigens (HY-Abs) were detected three months after F→M HCT, and the cumulative number of HY-Abs was significantly associated with increased risks of chronic GVHD and non-relapse mortality. This review focuses on F→M HCT, shedding light on its impact in several clinical settings and presenting clinical evidence of its allogeneic response, encompassing GVHD and graft-versus-leukemia (GVL) effects. Additionally, potential clinical options to mitigate adverse effects in F→M HCT will be discussed. Further investigation is required to improve clinical outcomes and understand allogenic immunological reconstitution after F→M HCT. |
| فهرسة مساهمة: | Keywords: Graft-versus-host disease; Graft-versus-leukemia effect; HY immunity; Sex-mismatched hematopoietic cell transplantation |
| تواريخ الأحداث: | Date Created: 20240429 Date Completed: 20240429 Latest Revision: 20240429 |
| رمز التحديث: | 20240501 |
| DOI: | 10.11406/rinketsu.65.265 |
| PMID: | 38684437 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 0485-1439 |
|---|---|
| DOI: | 10.11406/rinketsu.65.265 |